Hookipa Pharma Sells HBV and HIV Assets to Gilead
I'm PortAI, I can summarize articles.
HOOKIPA Pharma Inc. has completed the sale of its HB-400 and certain HB-500 program assets to Gilead Sciences, Inc. This transaction involves assets related to the clinical development of treatments for hepatitis B and HIV.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments